HCV Genotype 1 - 6 / HCV Subtypes Variants

Genotype 1 and 4 Articles

Genotype 2 and 3 Articles

Genotype 5 and 6 Articles

Genotypes 1 and 4

74 Percent of Genotype 1 HCV Patients in Experimental HCV PI Boceprevir Phase II Study Achieve Sustained Virologic Response (SVR) at 48 Weeks - 8/05/2008

Adequate Ribavirin Exposure after the First Dose Predicts Sustained Virological Response to Hepatitis C Treatment in Genotype 1 Patients - 7/08/08

HCV Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite Rapid Virological Response - 7/04/08

Vertex and Tibotec Start Phase 3 Study of Telaprevir for Treatment-Naive Genotype 1 Hepatitis C Patients - 3/21/08

Pegylated Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4 - 1/08/08

How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50? - 11/30/07

HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone  - 5/22/07

Epidemiological Characteristics and Treatment Outcomes in Individuals with Genotype 4 HCV Infection    - 7/10/07

Asians with Genotype 1 HCV Respond as Well as Whites to Interferon-based Therapy  - 5/25/07

Selected Patients with Genotype 1 HCV May Attain SVR by Extending Treatment Duration to 72 Weeks  - 4/24/07

400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV  - 4/24/07

Telaprevir-based Therapy for HCV May Shorten Treatment Duration from 48 to 24 Weeks for Some Genotype 1 Patients  - 4/17/07

Report of Hepatitis C Virus Genotype Recombination  2/16/07

Liver Steatosis in Genotype 4 Patients Is Mainly Due to Metabolic Factors   - 2/09/07

Genotypes 2 and 3

Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin - 8/12/2008

Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) - 8/05/2008

12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients - 7/11/08

European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load - 7/04/08

Studies Explore Lower Doses of Pegylated Interferon and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3 - 7/08/08

Limitations of an 8-week Course of Pegylated interferon plus Ribavirin for Genotype 2 Hepatitis C Patients with Rapid Virological Response - 4/24/08

Genetic Variations in HCV Genotype 3 Core Protein Promote Liver Fat Accumulation - 2/26/08

Asians with HCV Genotype 3 Do Not Respond as Well as Caucasians to Interferon-based Therapy - 2/19/08

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08

Insulin Resistance Linked to Lower Treatment Response in Genotype 2/3 Patients - 2/01/08

Liver Steatosis Is Common in Hepatitis C Patients, Especially Those with Genotype 3 - 2/01/08

Duration of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3 - 1/29/08

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08

Pegylated Interferon Alfa-2a Plus Ribavirin for 16 or 24 Weeks in Patients with Genotype 2 or 3 HCV Infection   - 7/20/07

Both Pegasys/Ribavirin and PegIntron/Ribavirin Combination Regimens Appear Similar in Efficacy and Safety in HCV Genotype 3 Patients  - 5/22/07

HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone  - 5/22/07

Treatment with Pegasys Plus Ribavirin in Genotype 2/3 Chronic Hepatitis C Patients with Liver Cirrhosis  - 5/22/07

Treatment Duration and Response in Patients with Genotype 2 or 3 HCV Infection  - 5/01/07

14 Weeks of Treatment with PegIntron plus Ribavirin Is Non-inferior to 24 Weeks in Rapid Responders with HCV Genotype 2 or 3  - 4/20/07

Past Psychiatric Disorders Do Not Reduce Hepatitis C Treatment Effectiveness in Genotype 2/3 Patients  - 4/20/07

Genotypes 5 and 6 Articles (Genotype 5 - Africa / Genotype 6 - South East Asia)

Epidemiology and Treatment Response of Genotype 5 HCV; Researchers Find New Seventh Genotype - 11/27/07

HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone  - 5/22/07

Does Weight-based Ribavirin Dosing Increase Sustained Viral Response in Patients with Chronic Hepatitis C? Final Results of the WIN-R Study - 11/18/05

Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6 - 10/21/05

First Report of Hepatitis C Virus Genotype 6 Infection in India - 6/22/5